http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-46935-U1
Outgoing Links
Predicate | Object |
---|---|
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 |
filingDate | 2004-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2005-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate | 2005-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-46935-U1 |
titleOfInvention | MEDICINAL PREVENTIVE PRODUCT BIOSEPTIN |
abstract | The utility model relates to biotechnology, namely to the production of probiotic biologics in ointment, granular or encapsulated forms. The technical result of the utility model is to increase the effectiveness of the probiotic preparation and expand its scope by creating ointment, granular and encapsulated forms of this drug for the prevention and treatment of diseases of the gastrointestinal tract, skin diseases and urogenital infections. The BIOSEPTIN therapeutic and prophylactic preparation includes a gel base with an active component distributed in its mass, which is used as a biomass of bacteria of the genus Bacillus. In addition, the preparation additionally contains a preservative, as a gel base it contains agar-agar mixed with biomass spores of bacteria of the genus Bacillus, which has a titer in the final preparation of at least! About 6 cells / g, and the finished form of the therapeutic product is made in the form of granules, or placed in a single-use cylindrical hollow detachable capsule, or a container with a lid with the following content of the drug components (wt.%): Preservative 5.0-20.0 agar-agar containing bacteria of the genus Bacillus with a titer of at least 10 6 spores / g, the rest up to 100%. 6 C.p.F., 3 tablets, 3 ill. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2593788-C2 |
priorityDate | 2004-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.